Colchicina um possível fármaco para o tratamento da COVID-19: uma revisão integrativa

Abstract

Colchicine is one of the most well-known anti-inflammatory drugs in contemporary clinical practice, and is indicated in a variety of inflammatory diseases including rheumatic diseases, gout, osteoarthritis, Behcet's disease, familial Mediterranean fever (FFM), pericarditis, atherosclerosis, and cardiovascular and liver diseases. Due to its immunomodulatory, anti- inflammatory and antiviral properties researchers have awakened to the use of this drug in the treatment of the symptoms of COVID-19. This disease is a respiratory pathology similar to influenza and can become a severe respiratory disease, causing organ dysfunction and leading to death. The objective of this paper was to present scientific evidence related to the efficacy of the drug Colchicine in the treatment of Covid-19. The methodology used was an integrative systematic review in the following databases: Bireme, Lilacs, PubMed, Science Direct, Scientific Electronic Library Online (SciELO) and JamaNetwork. The descriptors used in combination, from consultation in the "Descriptors in Health Sciences" (DECS) and Medical Subject Headings (MeSH), were: Colchicine, COVID-19, pandemic and their correspondents in English and Spanish, published in the period 2019 to 2021. In the data search, 634 articles were selected, after a careful analysis of the articles, 6 were eligible and included in this review. The articles analyzed, suggest Colchicine as an alternative treatment in infected patients, due to a probable reduction of pulmonary complications related to COVID-19, however, with the current studies, there is not enough evidence to indicate colchicine as part of the treatment in SARS-Cov-2 infection, being necessary more randomized and double blind clinical trials involving the use of this drug for a better evaluation of its effectiveness.